New Launches Drive Alembic Pharma to Strong Q1 Performance

Alembic Pharma started FY27 with a strong first quarter. The company reported healthy growth in profit and revenue.

Its performance was supported by new product launches, volume growth, and steady execution across key markets. The company's Q1 performance reflected broad-based growth across its businesses.

The pharmaceutical company reported a consolidated net profit of INR 173.07 crore for the quarter ended June 2026. This marked a 12.1% increase from INR 154.38 crore reported in the same quarter last year.

Its consolidated revenue from operations reached INR 2,149.77 crore. The company had reported revenue of INR 1,710.72 crore during the corresponding quarter of the previous financial year.

Profit Grows Despite Higher Expenses

Alembic Pharma also reported higher operating expenses during the quarter. Total expenses increased to INR 1,943.23 crore. In the same period last year, expenses stood at INR 1,526.67 crore.

Despite the increase in costs, the company maintained healthy earnings growth. Higher sales and improved business performance helped offset the rise in expenses. The latest quarterly numbers indicate that demand remained steady across multiple business segments.

Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market

New Product Launches Support Growth

Commenting on the quarterly performance, Pranav Amin, Managing Director of Alembic Pharmaceuticals Ltd, said the company has started FY27 on a strong note. He said growth was seen across all major businesses during the quarter.

According to him, healthy volume growth, successful product launches, and consistent execution across important markets supported the company's overall performance. The management believes these factors helped deliver balanced growth during the first quarter.

Key Takeaways From Alembic Pharma's Q1 Results

Alembic Pharma's latest earnings reflected growth across both profitability and sales.

Key highlights include:

• Consolidated profit increased 12.1% year-on-year.
• Profit stood at INR 173.07 crore for the June quarter.
• Revenue from operations rose to INR 2,149.77 crore.
• Total expenses increased due to higher business activity.
• New product launches supported overall growth.
• Healthy volume growth strengthened quarterly performance.
• The company began FY27 with broad-based business growth.

The strong start to FY27 shows Alembic Pharma continues to expand its business through higher sales, product launches, and consistent execution. While operating costs increased during the quarter, improved revenue growth helped the company deliver higher profits. The latest results also highlight the company's focus on strengthening its position across key markets while maintaining steady business momentum.